Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of treatment of TNBC breast cancer with neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab , including the incidences and types of adverse events. The secondary study objective is to observe and evaluate the event-free survival (EFS), Objective Response Rate(ORR), and radiologic complete response (rCR).

NCT Number	NCT07351487
Lead Sponsor	First Affiliated Hospital of Zhejiang University
Conditions	TNBC - Triple-Negative Breast Cancer
Enrollment	37 participants
Start Date	2025-09-25
Primary Completion	2028-09-25 (estimated)
Study Completion	2030-09-25 (estimated)
Updated on ClinicalTrials.gov	2026-01-20